肯尼亚城郊儿童轮状病毒疫苗接种对轮状病毒及全因胃肠炎的影响
研究比较肯尼亚中部一家大型转诊医院2014年7月引入单价轮状病毒疫苗前后,5岁以下儿童因轮状病毒胃肠炎和全因急性胃肠炎住院的变化。接种后第一年轮状病毒住院比例下降30%(95%CI:19-45%),第二年下降64%(95%CI:49-77%);全因急性胃肠炎住院第一年下降31%(95%CI:24-40%),第二年下降58%(95%CI:49-67%)。
要点
- 5岁以下儿童轮状病毒住院比例接种后第一年下降30%,第二年下降64%。
- 5岁以下儿童全因急性胃肠炎住院第一年下降31%,第二年下降58%。
- 接种后G2P[4]、G3P[6]和G3P[8]检出增加,与疫苗引入时间吻合。
核心结论
- 在肯尼亚常规免疫规划中引入轮状病毒疫苗后,肯尼亚中部轮状病毒和全因急性胃肠炎住院均显著下降。
- 作者认为这为肯尼亚公共卫生政策制定者支持在常规免疫中持续使用轮状病毒疫苗提供了早期证据。
研究设计与样本
- 比较疫苗前(2009年7月至2014年6月)与疫苗后(2014年7月至2016年6月)两个时期,5岁以下儿童全因急性胃肠炎和轮状病毒急性胃肠炎住院及毒株分布的变化。
- 轮状病毒急性胃肠炎和毒株分布数据来自正在进行的医院急性胃肠炎监测,全因急性胃肠炎趋势使用医院行政数据。
- 研究地点为肯尼亚中部一家大型转诊医院,服务人群以城郊人口为主。
主要发现
- 5岁以下儿童因轮状病毒住院的比例在接种后第一年下降30%(95%CI:19-45%),第二年下降64%(95%CI:49-77%)。
- 接种后第一年,疫苗可接种年龄组(<12月龄)轮状病毒阳性率下降最明显,为42%(95%CI:28-56%)。
- 接种后第二年,12-23月龄组轮状病毒阳性率下降67%(95%CI:51-79%)。
- 5岁以下儿童全因急性胃肠炎住院在接种后第一年下降31%(95%CI:24-40%),第二年下降58%(95%CI:49-67%)。
- 轮状病毒和全因急性胃肠炎的季节性高峰均大幅降低,G2P[4]、G3P[6]和G3P[8]检出增加与疫苗引入时间在时间上吻合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A monovalent rotavirus vaccine (RV1) was introduced into the National Immunization Program in Kenya in July 2014. We examined the impact of the vaccine on hospitalization for all-cause acute gastroenteritis (AGE) and rotavirus-specific AGE and strain distribution at a large referral hospital which serves a predominantly peri-urban population in Central Kenya. Data on rotavirus AGE and strain distribution were derived from ongoing hospital-based AGE surveillance. Hospital administrative data were used to compare trends in all-cause AGE. Pre-vaccine (July 2009-June 2014) and post-vaccine (July 2014-June 2016) periods were compared for changes in hospitalization for all-cause AGE and rotavirus AGE and strain distribution. Following the vaccine introduction, the proportion of children aged <5years hospitalized for rotavirus declined by 30% (95% CI: 19-45%) in the first year and 64% (95% CI: 49-77%) in the second year. Reductions in rotavirus positivity were most pronounced among the vaccine-eligible group (<12months) in the first year post-vaccination at 42% (95% CI: 28-56%). Greater reductions of 67% (95% CI: 51-79%) were seen in the second year in the 12-23months age group. Similarly, hospitalizations for all-cause AGE among children <5years of age decreased by 31% (95% CI: 24-40%) in the first year and 58% (95% CI: 49-67%) in the second year of vaccine introduction. Seasonal peaks of rotavirus and all-cause AGE were reduced substantially. There was an increased detection of G2P[4], G3P[6] and G3P[8], which coincided temporally with the timing of the vaccine introduction. Thus, introducing the rotavirus vaccine into the routine immunization program in Kenya has resulted in a notable decline in rotavirus and all-cause AGE hospitalizations in Central Kenya. This provides early evidence for public health policy makers in Kenya to support the sustained use of the rotavirus vaccine in routine immunizations.
引用
- Wandera EA, Mohammad S, Bundi M, et al. Impact of rotavirus vaccination on rotavirus and all-cause gastroenteritis in peri-urban Kenyan children. Vaccine. 2017. PMID: 28780116. doi:10.1016/j.vaccine.2017.07.096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。